Viking Therapeutics, Inc.
VKTX
$31.32
-$0.40-1.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.73% | -26.04% | -37.49% | 40.21% | 41.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 195.89% | 256.28% | 169.62% | 118.99% | 62.79% |
| Operating Income | -195.89% | -256.28% | -169.62% | -118.99% | -62.79% |
| Income Before Tax | -246.98% | -345.16% | -264.02% | -194.66% | -66.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -246.98% | -345.16% | -264.02% | -194.66% | -66.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -246.98% | -345.16% | -264.02% | -194.66% | -66.80% |
| EBIT | -195.89% | -256.28% | -169.62% | -118.99% | -62.79% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -236.44% | -334.74% | -259.40% | -190.03% | -54.01% |
| Normalized Basic EPS | -236.42% | -334.91% | -257.79% | -190.00% | -53.96% |
| EPS Diluted | -236.44% | -334.74% | -259.40% | -190.03% | -54.01% |
| Normalized Diluted EPS | -236.42% | -334.91% | -257.79% | -190.00% | -53.96% |
| Average Basic Shares Outstanding | 3.12% | 2.39% | 1.27% | 1.58% | 8.32% |
| Average Diluted Shares Outstanding | 3.12% | 2.39% | 1.27% | 1.58% | 8.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |